Clinical Trials in Massachusetts

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Revolution Medicines, Inc.

Phase 3

670

Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey

2026-05-22

Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Revolution Medicines, Inc.

Phase 3

900

Arizona, California, Florida, Maryland, Massachusetts, Minnesota, Nevada, New York

2026-03-09

Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation

Tango Therapeutics, Inc.

Phase 1/2

183

Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts

2025-05-31

Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

NCT06597721Advanced Solid Tumor, PDAC, HNSCC

Adcendo ApS

Phase 1

210

Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas

2024-11-25

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Revolution Medicines, Inc.

Phase 3

500

Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts

2024-10-16

Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC

Revolution Medicines, Inc.

Phase 1/2

1,130

Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts

2024-05-24

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →